<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03923985</url>
  </required_header>
  <id_info>
    <org_study_id>SEID-Probiot</org_study_id>
    <nct_id>NCT03923985</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Effect of an Oral Probiotic on the Vaginal Flora</brief_title>
  <official_title>Clinical Trial to Evaluate the Effect of an Oral Probiotic (Food Supplement) Containing Lactobacillus Crispatus on the Vaginal Flora</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Palacios</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Palacios</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial to evaluate the effect of a probiotic containing Lactobacillus Crispatus on
      the vaginal flora
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 21, 2019</start_date>
  <completion_date type="Anticipated">October 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the number of Lactobacillus Crispatus on the vaginal flora</measure>
    <time_frame>Screening, month 2</time_frame>
    <description>Analysis of vaginal lactobacilli.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in vaginal PH</measure>
    <time_frame>Screening, month 2</time_frame>
    <description>PH measurement</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Vaginal Flora</condition>
  <arm_group>
    <arm_group_label>Active Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 tablet / day of probiotic containing 10 Mld L. crispatus during two months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic containing Lactobacillus Crispatus</intervention_name>
    <description>1 tablet / day of probiotic (275 mg of live probiotic lactic ferments: 10 Mld L. fermentum (SGL 10), 10 Mld L. gasseri, 10 Mld L. casei, 10 Mld L. acidophilus, 10 Mld L. crispatus) during 2 months.</description>
    <arm_group_label>Active Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy women between 18 and 45 years old

          -  Women without current symptoms of vaginal infection

          -  Negative bacteriological and clinical examination

        Exclusion Criteria:

          -  Women with vaginal infection

          -  Women with undiagnosed vaginal bleeding

          -  Patients with endometrial hyperplasia

          -  Suspicion of neoplasia or active neoplasia

          -  Women with intolerance, allergy or hypersensitivity to the components of the probiotic

          -  Women with immunosuppressive disorders or with HIV

          -  Women who are currently using probiotics by any route of administration

          -  Women who are using some treatment for vaginal sepsis

          -  Chronic decompensated noncommunicable diseases (diabetes mellitus, heart disease ...)

          -  Pregnant women or those with precocious menopause
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only Females</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Santiago Palacios, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Palacios</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Santiago Palacios, PhD</last_name>
    <phone>+34 91 578 05 17</phone>
    <email>ipalacios@institutopalacios.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eva M Soler, SC</last_name>
    <phone>+34 91 578 05 17</phone>
    <email>eva.maria.soler@institutopalacios.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Palacios</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santiago Palacios, PI</last_name>
      <phone>+34 91 578 05 17</phone>
      <email>investigacion@institutopalacios.com</email>
    </contact>
    <contact_backup>
      <last_name>Eva M Soler, SC</last_name>
      <phone>+34 91 578 05 17</phone>
      <email>eva.maria.soler@institutopalacios.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 5, 2019</study_first_submitted>
  <study_first_submitted_qc>April 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2019</study_first_posted>
  <last_update_submitted>April 22, 2019</last_update_submitted>
  <last_update_submitted_qc>April 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaginal Flora</keyword>
  <keyword>Oral Probiotics</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

